Barnabas - Cancer Diagnostics - Grosse Pointe Woods, MI, USA

Nandita Barnabas

Grosse Pointe Woods, MI, USA


Cancer Diagnostics


Human tissue and cancer expertise
Hands on executive scientist
Scientific advisor
Partnerships within biotechnology and medicalindustries
Assay development and validation
Scientific product development
Peer reviewed publications in scientific journals
Molecular diagnostics
Clinical and research laboratory management
Scientific writing

Work History

Senior Scientific Project Administrator


From January 2013

Asterand is the leading global provider of high quality well characterized human tissue and human tissue-based research
solutions to drug discovery scientists. Provided scientific expertise to leadership team, sales and operation personnel to better understand and meet customer needs. Responsible for identifying new technologies in academia and biotech based on Asterand's key goals and objectives and making initial scientific evaluation

Scientific writing of articles, presentations and summaries for sales personnel, standard operating protocols

Academic and government contracted project management.

Clinical data management for The Cancer Genome Atlas Project (TCGA).

Resolve TCGA clinical data issues with the TCGA Biospecimen Core Resources.

Independent genotype review for TCGA sample sets

Scientific Strategy Associate


May 2011 - December 2012

Identified, negotiated, and made initial scientific evaluation for opportunities with academic and biotech collaborators and consultants.
Participated and presented new technologies at Scientific Leadership Team meetings.

Identify future indicators/characterization for bio-repository samples forecasting demand for human tissue.

Spearheaded cross-functional initiative re-establishing quarantined samples in inventory resulting in increased revenue.
Published first author cell line review that resulted in Boost of cell line sales entitled Phenotypic and Molecular characterization of Asterand Breast Cell Lines- International Journal of Breast cancer 2013.
Contributing author for Nature paper as a result of Asterand's collaboration with TCGA entitled Genomic Characterization of Endometrial Carcinoma".
Managed projects and provided scientific recommendations and analytical services for business critical, special projects (e.g. Mutation, SNP, sequencing, and IHC testing).
Worked with Chief Scientific Officer to write grant and government contract proposals.

Postdoctoral Fellow


January 2009 - December 2010

Focus of Research: Cancer of the female genital tract
Communicated first author paper for publication entiltled"Array-CGH shows high-level of amplification of 8q including MYC as the sole aberration in a Leiomyosarcoma of the female lower genital tract
Findings indicated that high-level amplification of 8q including MYC is a primary genetic abnormality as well as a pathway of evolution in Leiomyosarcoma
Fellowship in Cytogenetics in accordance with the American Board of Medical Genetics regulations Clinicalinterpretation of Cytogenetics results Laboratory management supervising technical staff.

Research Scientist/Instructor


July 1999 - December 2008

Focus of Research: Prostate Cancer diagnostics
Published first author paper entitled "Chromosome 8 markers of metastatic prostate cancer in African American men: Gain of the MIR151 gene and loss of the NKX3-1 gene.

Presented paper at the 6th Annual Michigan Prostate Research Colloquium entitled "Androgen Receptor Gene Mutations in Prostate Cancer".

Presented three first author papers at American Association Cancer Research symposiums entitled "A polymorphic variant of the Selanoprotein thioredoxin reductase type 3 is a risk factor for aggressive prostate
cancer in African Americans" & "Androgen receptor GGC (glycine) repeat length polymorphism in African American men with prostate cancer" & "Is androgen receptor CAG repeat length a risk factor for aggressive prostate cancer in African American men?"

Associate Staff Investigator


January 1997 - June 1999

Focus of Research: Breast, Kidney and Lymphoma Biomarkers
Published first author paper entitled " Mutations Compliment Prognostic and Differential Diagnostic Parameters in Renal Cell Carcinoma.
Discovered that mutations in the VHL gene refined histological diagnostic criteria in renal cell carcinoma serving as adjuncts to the current morphology based diagnosis
Published first author paper entitled "Significance of p53 mutations in CLL- A sequential study of 30 patients.

Discovered mutations in exon 7 of the p53 gene occurred in patients with clinically aggressive B- cell chronic lymphocytic leukemia.

Published first author paper entitled "Significance of p53 mutations in CLL- A sequential study of 30 patients.

Presented author paper at the Am Assoc of Cancer Research entitled ". BRCA 1 antibodies: Evaluation of germline mutations in breast and ovarian cancers".

Postdoctoral Research Associate


January 1991 - February 1996

Fox Chase Cancer Center is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center, one of only 41 centers in the country to qualify for this highest level of designation and its researchers are frequently involved in setting new guidelines for breakthrough medicine and comprehensive care

Focus of Research: Breast Cancer Biomarkers
Published paper entitled "Microsatellite Instability and Loss of Heterozygosity of chromosomes 9 and 16 in

Human Breast Epithelial Cells Transformed by Chemical Carcinogens.
Published paper entitled " Mini Review: Molecular basis of Breast Cell Transformation.

Published first author paper entitled " Role of p53 in the transformation of human breast epithelial cell line MCF 10F.
Discovered p53 mutations in the spontaneously immortalized breast cell line MCF 10F compared to its mortalized counterpart. MCF 10F cell lines are susceptible to chemically induced neoplastic transformation.
Published two papers entitled "Genomic scanning using endogenous LTR-like elements for rapid DNA fingerprinting of breast cancer and transformed human breast epithelial cells. & "Co- expression of C-erbB2 and Int-2 oncogenes in invasive breast carcinomas.
Demonstrated alteration in genomic DNA in a clones of chemically transformed tumorigenic breast cancer cell lines using the DNA fingerprinting technology
Discovered the presence of mutations in C-erbB2 and Int-2 oncogenes in Egyptian patients with histological high grade invasive breast carcinoma's

Postdoctoral fellow


June 1989 - December 1990

Focus of Research: Breast Cancer Biomarkers
Published first author paper entitled"Breast carcinoma in a high-risk population: Structural alterations in neu. int-2. and p-53 genes.
Discovered structural alterations in neu, Int-2. and p-53 genes in breast cancer of Parsi women.


Core accomplishements

Key scientific advisor for government grant funded project resulting in increased revenue for business
Scientific Affairs Liaison working with physicians and scientists
Scientific writing for grants, peer review publications, technical writing and standard operating protocols
Published review for company which resulted in boost of cell lines sales
Discovered biomarker in Leiomyosarcoma
Laboratory management: supervising clinical technical staff during fellowship training
Mentored graduate students in grant and thesis writing which resulted in graduation, publications and grant
funding for projects
Clinical interpretation of Cytogenetics during two year Fellowship in Cytogenetics

Qualifications & Certifications


University of Poona


University of Poona

Skillpages has been acquired by! is pioneering the way people find local services. Skillpages is the world’s premier directory of service providers.

Find out more

Supported Countries
Choose your country